Aaronson and Rash

Free Case Review


Every year, thousands of Americans are hurt or killed by dangerous and defective pharmaceutical products. These drugs may cause serious side effects ranging from diabetes to cardiac arrest to birth defects. The Centers for Disease Control & Prevention (CDC) reports that pharmaceutical drugs kill more than 40,000 people every year.

Large pharmaceutical companies are responsible for the research and development of their products and must include warning labels on any product that may cause side effects. These large pharmaceutical companies do not tell doctors about the side effects either because the company failed to test their drug properly or the company knew of the risk and chose to hide it for economic benefit. When these companies fail to disclose these side effects a consumer and their doctor cannot make an effective decision about the risks and benefits of the use of a drug.

Our team of Pharmaceutical Attorneys at Aaronson & Rash, PLLC represents victims of side effects caused by the use of dangerous drugs. We are experienced, knowledgeable, and dedicated to the interests of our clients. Our Pharmaceutical Attorneys are currently accepting new clients for the following cases:

Invokana Lawsuit


Invokana is a SGLT2 inhibitor used to treat Type-2 diabetes in adult patients. Combined with diet and exercise, it lowers blood sugars and improves glycemic control. In May 2015, the FDA issued a Drug Safety Communication warning about the risks of drugs like Invokana. The FDA stated SGLT2 inhibitors could cause the body to produce high levels of blood acids called ketones that may require hospitalization.




Fournier’s Gangrene Attorney

FDA Warning: Diabetes Drugs Linked to Flesh-Eating Genital Infection

The FDA announced that some Type 2 diabetes medications including Invokana have been linked to cases of “necrotizing fasciitis of the perineum,” a “flesh eating” genital infection also called Fournier’s gangrene. The warning comes after the FDA identified cases of the disease in patients taking a SGLT2 inhibitor over the course of 5 years, between March 2013 to May 2018.